Navigation Links
Exelixis Announces November 28 Webcast of Presentation at the Lazard Capital Markets Fourth Annual Healthcare Conference
Date:11/21/2007

SOUTH SAN FRANCISCO, Calif., Nov. 21 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL) announced today that George A. Scangos, Ph.D., the company's president and chief executive officer will present at the Lazard Capital Markets Fourth Annual Healthcare Conference at 1:00 p.m. ET / 10:00 a.m. PT on Wednesday, November 28, 2007.

The presentation will be webcast and may be accessed in the Event Calendar page under Investors on the Exelixis website at http://www.exelixis.com.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 2 and phase 1 clinical development for cancer and renal disease. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb Company, Genentech, Wyeth Pharmaceuticals and Daiichi-Sankyo. For more information, please visit the company's web site at http://www.exelixis.com.


'/>"/>
SOURCE Exelixis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related biology technology :

1. Dow AgroSciences and Exelixis Plant Sciences Announce Major Research Collaboration, Asset Purchase to Advance Gene Discovery and Validation
2. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
3. Exelixis Announces Closing of Public Offering of Common Stock
4. Exelixis Submits XL880 Diligence Report to GlaxoSmithKline
5. Exelixis Announces November 5 Webcast of its 2007 Third Quarter Financial Results Conference Call
6. Exelixis Announces Third Quarter 2007 Financial Results and Business Update
7. Exelixis Sells 80% Stake in Artemis to Taconic
8. Exelixis Announces December 5 Webcast of Its Third Annual R&D Day
9. Exelixis Announces November 27 Webcast of Presentation at the 19th Annual Piper Jaffray Health Care Conference
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)... The New York investment bank KTA Capital... agreed an AU$6.7 mil convertible note private pla...vate placement was arranged by KTA Capital as Neur... New York (PRWEB) November 23,...KTA Capital, LLC ("KTA Capital") has ann...
(Date:11/24/2009)... , REYKJAVIK, Iceland, November 24 /PRNe...: DCGN ) today announced that it has received noti...e company,s common stock will be,suspended as of N...ith the,Securities and Exchange Commission, which ...Nasdaq, unless the company files an appeal to the ...
(Date:11/24/2009)... , REYKJAVIK, Iceland, November 24 /PRNe...: DCGN ) today announced the approval of all of it... for the District of Delaware,(the "Bankruptcy Cou...for,relief under Chapter 11 of the United States B... The orders issued by the Bankruptcy Court allow...
(Date:11/24/2009)... SHANGHAI, Nov. 24 /PRNewswire-Asia/ -- Shangh...Drug Administration (SFDA) has approved the,invest...insulin project,(Nodlin), an innovative insulin fo...ows Biolaxy to initiate its first phase I clinical...ristic of high blood glucose and poor,metabolism. ...
Breaking Biology Technology:KTA Capital Arranges an AU$6.7 Million Private Placement by Neuren Pharmaceuticals 2deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 2deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 3deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 2deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 3Biolaxy Secures IND Approval for Oral Insulin 2
... , Shareholders are Urged to Vote their YELLOW ...d and Independent Directors to the Biovail Board, ...Shareholders of Biovail today said that Biovail Co...lead its shareholders by making the focal point of...mply about governance reform and has already been ...
... Results from Phase 2 Clinical Trials of Carfilzom...anced Solid Tumors Featured in Oral Presentations ...today announced that data from clinical trials of ... tumors will be presented at the 2009 Annual Meeti...SCO) being held May 29 - June 2, 2009 in Orlando, ...
... LA JOLLA, Calif., May 15 Fate Therapeutics, In...e intellectual property rights jointly owned by Ch... Hospital. This intellectual property covers comp...stem cells. These proprietary technologies develo...l Program at Children,s Hospital Boston and a scie...
Other Biology Technology:The Concerned Shareholders of Biovail Say Biovail Has Misled Shareholders 2The Concerned Shareholders of Biovail Say Biovail Has Misled Shareholders 3The Concerned Shareholders of Biovail Say Biovail Has Misled Shareholders 4The Concerned Shareholders of Biovail Say Biovail Has Misled Shareholders 5The Concerned Shareholders of Biovail Say Biovail Has Misled Shareholders 6The Concerned Shareholders of Biovail Say Biovail Has Misled Shareholders 7Proteolix to Present Carfilzomib Clinical Data During the 2009 ASCO Annual Meeting 2Proteolix to Present Carfilzomib Clinical Data During the 2009 ASCO Annual Meeting 3Fate Therapeutics Granted Exclusive License for Stem Cell Modulators by Children's Hospital Boston and Massachusetts General Hospital 2Fate Therapeutics Granted Exclusive License for Stem Cell Modulators by Children's Hospital Boston and Massachusetts General Hospital 3
(Date:11/25/2009)... Sarit Larisch, Head of the Cell Death Research La...f Biology, has been awarded the prestigious Johnso... exploring the cause of brain cell damage in Parki...ear to scientists in support of innovation and exc...icially conferred earlier this month at an event a...
(Date:11/24/2009)...housands of years it has been prescribed by tradit...ts from headaches and stomach pain to fever and fl...stle University have been able to scientifically p...ata otherwise known as Brazilian mint. , Testin...am led by researcher Graciela Rocha was able to sh...
(Date:11/24/2009)...tomic-level action of a remarkable class of ring-s...hers with the Lawrence Berkeley National Laborator...crystallography beamline at the Advanced Light Sou... in gene expression and replication, and are vital...as infectious agents, such as the human papillomav...
Breaking Biology News(10 mins):Johnson & Johnson award goes to research of the cause of brain cell damage in Parkinson's 2Got a pain? -- Have a cup of Brazilian mint 2Atomic-level snapshot catches protein motor in action 2Atomic-level snapshot catches protein motor in action 3Atomic-level snapshot catches protein motor in action 4A Safety Slip 3A Dont Hold a Child in Your Lap on Playground Slides 56173 1A Safety Slip 3A Dont Hold a Child in Your Lap on Playground Slides 56173 2Americas No 1 Pharmacy Names Great Health as Its Exclusive Health and Wellness Magazine 56168 1Rodgers Introduces SamarionSolution to International Audience 56164 1Rodgers Introduces SamarionSolution to International Audience 56164 2
...ational group of researchers today unveiled a deta...or histocompatibility complex (MHC), the most impo...n response to infection, autoimmune disease and or...ne in the analysis of genetic variability for this... foundation for future efforts aimed at uncovering...
...,s most widely used organic insecticide, a plucky ...r short, requires the assistance of other microbes...as found. , Writing in the Sept. 26 issue of the ...NAS), a team of researchers from the University of...f the native bacteria that colonize the insect gut...
...rs have achieved an effective immune response to a...-quarter of the norm when they added a chemical mi...the November 1 issue of Clinical Infectious Diseas...--a substance that increases the immune system,s a..., the investigators used inactivated H9N2 influenz...
Other Biology News:International team analyzes human genetic variation in key immune region 2International team analyzes human genetic variation in key immune region 3Most widely used organic pesticide requires help to kill 2Most widely used organic pesticide requires help to kill 3
Adaptor Hind III - Sma I from Takara Mirus Bio
DryStrip aligners from GE Healthcare, formerly Amersham Biosciences
Normal Calf Serum from Equitech-Bio
... at the 3, 3', 4, and 4' positions. It is intended...ation of PGE1 by GC- or LC-mass spectrometry. PGE1...ihomo-γ-linolenic acid (DGLA), but it is vi...s or other animals. Its pharmacology includes vaso...
Biology Products: